Dr. Allison on the Development of Ipilimumab for Cancer Treatment


In Partnership With:

James P. Allison, PhD, discusses the development of ipilimumab.

James P. Allison, PhD, chair, Immunology, executive director, Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, and a recipient of the 2018 Nobel Prize in Physiology or Medicine, discusses the development of ipilimumab (Yervoy).

When developing ipilimumab, a monoclonal antibody, bias against immunotherapy presented the biggest challenge at the time, according to Allison. Allison focused his research on mechanisms and the regulation of T-cell responses and tried to apply this work to the treatment of patients with cancer. During his research, he found that blocking checkpoints could unleash the immune system’s T cells.

Allison anticipated doubts about this strategy, and he completed research in mouse models with various strains and tumors to ensure ipilimumab would work as monotherapy, radical chemotherapy, radiation, or vaccine.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD